PRLDPrelude Therapeutics Incorporated
Price
+169%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Prelude Therapeutics Incorporated (PRLD) reported revenue of $5.7M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $14M. For the full year FY2025, revenue was $12M (+73% year on year) and net income −$99M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader.Regulation FD disclosure · press release
- Aug 11, 2026Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- May 12, 2026Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.